What researchers published on Fatty liver disease (MASLD/MASH)
7,857 papers, newest first.
Showing 20 of 7,857
ReviewHepatocyte-derived lipid droplets in MASH: macrophage sensing and inflammation.Frontiers in immunology
Not labelled yetUnresolved questions for nutrient-stimulated hormonal multi-agonists in MASH; more receptors, better livers?: Editorial on "Engineered nutrient-stimulated hormonal multi-agonists for precision targeting of obesity and metabolic disorders".Clinical and molecular hepatology
ReviewDietary interventions in metabolic dysfunction-associated steatotic liver disease: current evidence, research priorities, and clinical translation.Clinical and experimental hepatology
Not labelled yetLiquiritigenin Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease via AMPK-Mediated Dual Activation of PPARα/PPARγ.Food science & nutrition
Not labelled yetNeuro-immune and metabolic disorders in association with depression, anxiety, and chronic fatigue-fibromyalgia symptoms due to nonalcoholic fatty liver disease.CNS spectrums
Case reportGlycogenic Hepatopathy Mimicking Overlapping with Metabolic Dysfunction-Associated Steatotic Liver Disease in Newly Diagnosed Type 2 Diabetes: A Case Report.SAGE open medical case reports
Not labelled yetComment on "Effect of High Dose N-Acetyl Cysteine Supplementation on Markers of Oxidative Stress and Insulin Resistance in Non-Diabetic Patients With Metabolic Dysfunction Associated Steatotic Liver Disease: A Randomized Controlled Trial".Journal of gastroenterology and hepatology
ReviewEffects of Bacterial-Derived Extracellular Vesicles in Rodent Models of Obesity, Metabolic Dysfunction-Associated Steatotic Liver Disease and Insulin Resistance/type 2 Diabetes. A Systematic Review.Probiotics and antimicrobial proteins
Not labelled yetPropolis Supplementation in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Phytotherapy research : PTR
Not labelled yetNumerical reproducibility and threshold interpretation in MASLD risk stratification.Clinical and molecular hepatology
Not labelled yetLetter to the Editor on "Normal-weight MASLD: reclassification, characteristics, and adverse liver outcomes across diverse populations".Clinical and molecular hepatology
Not labelled yetEfinopegdutide: a step towards precision in MASH therapy?Lancet (London, England)
Not labelled yetWhat Does Normal BMI Hide in MASLD? Body Composition and Cause-Specific Mortality After Reclassification: Authors' reply.Clinical and molecular hepatology
Not labelled yetGLP-1/Glucagon Receptor Dual Agonists for Metabolic Dysfunction-Associated Steatohepatitis and Steatotic Liver Disease (MASH/MASLD): A Systematic Review and Meta-Analysis.Digestive diseases (Basel, Switzerland)
Not labelled yetTMEM189/PEDS1 deficiency aggravates MASH progression by promoting FASN-mediated macrophage activation.Cell death & disease
Not labelled yetClarifying local price mapping, response thresholds, and re-treatment structure in MASLD cost-effectiveness modeling.Clinical and molecular hepatology
Not labelled yetSaroglitazar Facilitates Insulin De-escalation and Improves Metabolic Parameters in Pioglitazone-Ineligible Non-metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Type 2 Diabetes: Real-World Evidence From India.Cureus
Not labelled yetQuantitative fragility of reported association between aspirin use and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease: Letter to the editor on "Aspirin and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease: Nationwide cohort study with genetic risk analysis".Clinical and molecular hepatology
Not labelled yetA Liver-Targeted CIDEB siRNA in Adults with MASLD.The New England journal of medicine
Not labelled yetReply: Thoughts on the clinical translation of dynamic fibrosis risk assessment models in MASLD.Clinical and molecular hepatology